文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Adjuvant personalized cancer vaccine: is this the end of metastatic kidney cancer.

作者信息

Schmidinger Manuela, Huebner-Resch Irene

机构信息

Department of Urology, Medical University of Vienna and Comprehensive Cancer Center, Vienna, Austria.

出版信息

Nat Rev Urol. 2025 Mar 27. doi: 10.1038/s41585-025-01018-6.

DOI:10.1038/s41585-025-01018-6
PMID:40148578
Abstract
摘要

相似文献

[1]
Adjuvant personalized cancer vaccine: is this the end of metastatic kidney cancer.

Nat Rev Urol. 2025-3-27

[2]
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.

Cochrane Database Syst Rev. 2012-3-14

[3]
A systematic overview of chemotherapy effects in breast cancer.

Acta Oncol. 2001

[4]
ctDNA-guided adjuvant immunotherapy in colorectal cancer.

Immunotherapy. 2024

[5]
Start Time End Time Integration (STETI): Method for Including Recent Data to Analyze Trends in Kidney Cancer Survival.

Healthcare (Basel). 2025-6-17

[6]
Adjuvant platinum-based chemotherapy for early stage cervical cancer.

Cochrane Database Syst Rev. 2012-6-13

[7]
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.

Cancer Control. 2024

[8]
Unmasking hidden metastasis: A case report of gastrointestinal metastasis detected a decade after breast cancer diagnosis.

Medicine (Baltimore). 2025-8-8

[9]
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial.

JMIR Res Protoc. 2025-8-26

[10]
Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer.

Cochrane Database Syst Rev. 2010-1-20

本文引用的文献

[1]
Pathology-oriented multiplexing enables integrative disease mapping.

Nature. 2025-7-18

[2]
Basis functions for complex social decisions in dorsomedial frontal cortex.

Nature. 2025-5

[3]
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

J Clin Oncol. 2025-1-10

[4]
Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma.

Oncologist. 2024-10-3

[5]
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.

Lancet Oncol. 2024-8

[6]
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

N Engl J Med. 2024-4-18

[7]
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.

Lancet. 2023-3-11

[8]
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.

Lancet. 2022-10-1

[9]
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

N Engl J Med. 2021-8-19

[10]
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).

Clin Cancer Res. 2021-6-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索